RSS Feed Print
Last remaining Bace inhibitor fails
Posted: Tuesday, September 17, 2019 6:23 AM
Joined: 2/26/2016
Posts: 263

The last remaining bace inhibitor in FDA clinical trials, Elenbecestat, developed by Biogen and Eisai, has failed for safety and effectiveness reasons. This drug was designed to decrease the buildup of amyloid in the brain.

Here are some of the bace inhibitors that I have found that failed in clinical trials in the last two years:

Verubecestat (Merck)

Lanabecestat (Astra Zeneca and Eli Lilly)

BI-1181181 (Boehringer Ingelheim)

Atabecestat (Johnson and Johnson)

Umibecestat (Novartis and Amgen)

CAD106 (Novartis and Amgen)

Elenbecestat (Biogen and Eisai)

Evidently reducing amyloid plaques isn't working. I think that maybe Big Pharma should be looking at safe drugs to reduce neuro-inflammation and slow down the aging brain's overactive immune system. After spending billions of dollars, they should know by now that even when amyloid plaques are reduced, inflammation and brain cell damage continue.